MONROVIA, Calif., Sept. 20, 2017 /PRNewswire/ -- Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical
company developing engineered monoclonal antibodies for the
treatment of autoimmune diseases, asthma and allergic diseases and
cancer, today announced that company management will present a
corporate update at two upcoming conferences:
- Cantor Fitzgerald Global Healthcare
Conference
Date: Wednesday,
September 27, 2017
Time: 1:40 p.m. ET
Location: New York, NY
- Leerink Partners Roundtable Series: Rare Disease &
Immuno-Oncology
Date: Thursday, September 28, 2017
Time: 8:30 a.m. ET
Location: New York, NY
Live webcasts of both events will be available on the "Events
& Presentations" section in the Investors section of the
Company's website located at
http://investors.xencor.com/events.cfm. A replay of the
presentations will be posted on the Xencor website approximately
one hour after the live events and will be available for 30 days
following the presentations.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of
autoimmune diseases, asthma and allergic diseases and cancer.
Currently, 11 candidates engineered with Xencor's XmAb®
technology are in clinical development internally and with
partners. Xencor's internal programs include: XmAb®5871
in Phase 2 development for the treatment of IgG4-Related Disease,
and also for the treatment of Systemic Lupus Erythematosus;
XmAb®7195 in Phase 1 development for the treatment of asthma and
allergic diseases; XmAb®14045 in Phase 1 development for acute
myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell
malignancies; XmAb®18087 in pre-clinical development for the
treatment of neuroendocrine tumors; and XmAb®20717 in pre-clinical
development for the treatment of multiple
cancers. Xencor's XmAb antibody engineering technology
enables small changes to the structure of monoclonal antibodies
resulting in new mechanisms of therapeutic
action. Xencor partners include Novartis, Amgen,
MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer
Ingelheim. For more information, please
visit www.xencor.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300521475.html
SOURCE Xencor, Inc.